Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

PROSHARES TRUST (ZBIO) EBITDA: 2023-2025

Historic EBITDA for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to -$51.5 million.

  • Zenas BioPharma's EBITDA fell 33.16% to -$51.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$190.0 million, marking a year-over-year decrease of 47.26%. This contributed to the annual value of -$156.8 million for FY2024, which is 323.34% down from last year.
  • As of Q3 2025, Zenas BioPharma's EBITDA stood at -$51.5 million, which was up 1.88% from -$52.5 million recorded in Q2 2025.
  • Zenas BioPharma's 5-year EBITDA high stood at $35.6 million for Q3 2023, and its period low was -$52.5 million during Q4 2024.
  • Over the past 3 years, Zenas BioPharma's median EBITDA value was -$37.9 million (recorded in 2024), while the average stood at -$31.5 million.
  • Data for Zenas BioPharma's EBITDA shows a maximum YoY slumped of 208.53% (in 2024) over the last 5 years.
  • Zenas BioPharma's EBITDA (Quarterly) stood at -$24.7 million in 2023, then crashed by 112.62% to -$52.5 million in 2024, then tumbled by 33.16% to -$51.5 million in 2025.
  • Its EBITDA was -$51.5 million in Q3 2025, compared to -$52.5 million in Q2 2025 and -$33.6 million in Q1 2025.